About the webinar:
Researchers studying prostate cancer often face challenges in murine models. Among them are their inability to fully recapitulate both anatomical and developmental features of the human disease and inability to form spontaneous prostate cancer. To resolve these core challenges, researchers have turned to a sophisticated solution: super immunodeficient mice xenografted with human cancer tissue or cells. These advanced tools can be used to characterize cancer progression and to assess the tumor’s response to therapeutics.
In this exclusive webinar, you’ll learn how Taconic’s huNOG mouse model has been successfully used in xenograft studies to model prostate cancer, including to test FDA-approved therapeutics. Dr. Steven Kregel will explore how these models help advance the preclinical-to-clinical pipeline and share recent data using huNOG mice engrafted with metastatic castration resistant prostate cancer. He’ll also review how the androgen receptor pathway may hold the key to developing the next generation of therapeutics.
Attend the webinar to:
- Learn how prostate cancer xenografts in huNOG mice mimic T cell inflamed tumors in human disease
- Discover how tumors in xenografted huNOG mice respond to both AR-inhibition and anti-PD1 immune checkpoint inhibitors
- Understand how a huNOG mouse model engrafted with human prostate cancer advances the preclinical-to-clinical pipeline
